Pinnacle Financial Partners Inc. Has $4.05 Million Holdings in Pfizer, Inc. (PFE)

Pinnacle Financial Partners Inc. grew its stake in Pfizer, Inc. (NYSE:PFE) by 36.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 120,651 shares of the biopharmaceutical company’s stock after buying an additional 32,089 shares during the quarter. Pinnacle Financial Partners Inc.’s holdings in Pfizer were worth $4,053,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. United Asset Strategies Inc. increased its position in Pfizer by 3.0% in the second quarter. United Asset Strategies Inc. now owns 80,749 shares of the biopharmaceutical company’s stock worth $2,712,000 after buying an additional 2,352 shares in the last quarter. Advisors Asset Management Inc. increased its position in Pfizer by 6.2% in the second quarter. Advisors Asset Management Inc. now owns 1,867,923 shares of the biopharmaceutical company’s stock worth $62,744,000 after buying an additional 109,478 shares in the last quarter. Signature Financial Management Inc. increased its position in Pfizer by 23.2% in the second quarter. Signature Financial Management Inc. now owns 30,697 shares of the biopharmaceutical company’s stock worth $1,032,000 after buying an additional 5,774 shares in the last quarter. Dividend Assets Capital LLC increased its position in Pfizer by 15.1% in the second quarter. Dividend Assets Capital LLC now owns 42,602 shares of the biopharmaceutical company’s stock worth $1,431,000 after buying an additional 5,590 shares in the last quarter. Finally, Convergence Investment Partners LLC increased its position in Pfizer by 2.6% in the second quarter. Convergence Investment Partners LLC now owns 265,176 shares of the biopharmaceutical company’s stock worth $8,907,000 after buying an additional 6,761 shares in the last quarter. Institutional investors and hedge funds own 69.36% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Pinnacle Financial Partners Inc. Has $4.05 Million Holdings in Pfizer, Inc. (PFE)” was originally published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.themarketsdaily.com/2017/11/16/pinnacle-financial-partners-inc-has-4-05-million-holdings-in-pfizer-inc-pfe.html.

A number of analysts have commented on the company. Deutsche Bank AG set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, October 10th. Barclays PLC set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Jefferies Group LLC set a $38.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $38.48.

Shares of Pfizer, Inc. (PFE) opened at $35.36 on Thursday. The stock has a market capitalization of $210,889.83, a P/E ratio of 14.15, a PEG ratio of 2.50 and a beta of 1.01. Pfizer, Inc. has a one year low of $30.51 and a one year high of $36.78. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same period last year, the company earned $0.61 EPS. sell-side analysts predict that Pfizer, Inc. will post 2.6 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.62%. The ex-dividend date is Thursday, November 9th. Pfizer’s payout ratio is 79.01%.

In other news, CEO Ian C. Read sold 197,168 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the completion of the sale, the chief executive officer now directly owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now directly owns 132,124 shares of the company’s stock, valued at $4,492,216. The disclosure for this sale can be found here. Insiders sold a total of 374,621 shares of company stock valued at $12,796,098 over the last ninety days. Corporate insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply